A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesROWINSKY, Eric K; BEERAM, Muralidhar; NGUYEN, Binh et al.Clinical cancer research. 2007, Vol 13, Num 2, pp 532-539, issn 1078-0432, 8 p., 1Article

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerRUDIN, Charles M; HANN, Christine L; RANSON, Malcolm R et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3163-3169, issn 1078-0432, 7 p.Article

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancerWAKELEE, Heather A; TAKIMOTO, Chris H; ZATLOUKAL, Petr et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 2, pp 563-571, issn 0344-5704, 9 p.Article

Detection of c-KIT and PDGFRA Gene Mutations in Gastrointestinal Stromal Tumors: Comparison of DHPLC and DNA Sequencing Methods Using a Single Population-Based CohortBATTOCHIO, Angeline; MOHAMMED, Shamayel; WINTHROP, Debra et al.American journal of clinical pathology. 2010, Vol 133, Num 1, pp 149-155, issn 0002-9173, 7 p.Article

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)RODON, Jordi; JACOBS, Charlotte D; CHU, Quincy et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 3, pp 825-834, issn 0344-5704, 10 p.Article

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid TumorsCHU, Quincy; MITA, Alain; FOROUZESH, Bahram et al.Clinical cancer research (Print). 2010, Vol 16, Num 9, pp 2656-2665, issn 1078-0432, 10 p.Article

A fishy conclusion regarding n-3 fatty acid supplementation in cancer patientsMURPHY, Rachel A; THOMAS CLANDININ, M; CHU, Quincy S et al.Clinical nutrition (Edinburgh). 2013, Vol 32, Num 3, pp 466-467, issn 0261-5614, 2 p.Article

Skeletal Muscle Depletion Is Associated with Reduced Plasma (n-3) Fatty Acids in Non-Small Cell Lung Cancer PatientsMURPHY, Rachel A; MOURTZAKIS, Marina; CHU, Quincy S et al.The Journal of nutrition. 2010, Vol 140, Num 9, pp 1602-1606, issn 0022-3166, 5 p.Article

Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancerKIM, Christina A. K; PRICE-HILLER, Julie; CHU, Quincy S et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 1036-1045, issn 0167-6997, 10 p.Article

Nutritional Intervention With Fish Oil Provides a Benefit Over Standard of Care for Weight and Skeletal Muscle Mass in Patients With Nonsmall Cell Lung Cancer Receiving ChemotherapyMURPHY, Rachel A; MOURTZAKIS, Marina; CHU, Quincy S. C et al.Cancer. 2011, Vol 117, Num 8, pp 1775-1782, issn 0008-543X, 8 p.Article

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumorsCHU, Quincy S; SANGHA, Randeep; HOTTE, Sebastien J et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1226-1235, issn 0167-6997, 10 p.Article

Supplementation With Fish Oil Increases First-Line Chemotherapy Efficacy in Patients With Advanced Nonsmall Cell Lung CancerMURPHY, Rachel A; MOURTZAKIS, Marina; CHU, Quincy S. C et al.Cancer. 2011, Vol 117, Num 16, pp 3774-3780, issn 0008-543X, 7 p.Article

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenibMEZA-JUNCO, Judith; CHU, Quincy S.-C; CHRISTENSEN, Olaf et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 1, pp 1-4, issn 0344-5704, 4 p.Article

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumorsMITA, Alain C; HAMMOND, Lisa A; WEITMAN, Steve et al.Clinical cancer research. 2006, Vol 12, Num 17, pp 5207-5215, issn 1078-0432, 9 p.Article

Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect StudyRICART, Alejandro D; SARANTOPOULOS, John; CALVO, Emiliano et al.Clinical cancer research (Print). 2009, Vol 15, Num 11, pp 3866-3871, issn 1078-0432, 6 p.Article

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesCHU, Quincy Siu-Chung; HAMMOND, Lisa A; DECILLIS, Arthur P et al.Clinical cancer research. 2004, Vol 10, Num 15, pp 4913-4921, issn 1078-0432, 9 p.Article

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced MalignanciesMITA, Monica M; MITA, Alain C; KNOWLES, Heather et al.Journal of clinical oncology. 2008, Vol 26, Num 3, pp 361-367, issn 0732-183X, 7 p.Article

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignanciesCHU, Quincy S. C; SCHWARTZ, Garry; HO, Peter T. C et al.Journal of clinical oncology. 2007, Vol 25, Num 24, pp 3753-3758, issn 0732-183X, 6 p.Article

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumoursDEVRIESE, Lot A; KOCH, Kevin M; BOTBYL, Jeff et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 481-488, issn 0167-6997, 8 p.Article